
Patent claims

1. 18-Methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-ones of the general formula I,



formula (1)

wherein R^6 and R^7 are a hydrogen atom or together are an α-methylene group, for use in the treatment of uterine bleeding disorders and haemorrhages.

2. 18-Methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-one for use in the treatment of menorrhagia.

3. 18-Methyl-6α,7α,15ß,16ß-dimethylene-19-nor-20-spirox-4-en-3-one for use in the treatment of menorrhagia.

4. Use of 18-methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-one according to Claim 2, characterized in that 18-methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-one is administered by the intrauterine route.

5. Use according to Claim 4, characterized in that 18-methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-one is administered using an intrauterine system.

6. Use according to Claim 4 or 5, characterized in that 18-methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-one is administered by way of a daily dose of 1-200 µg.

7. Use according to Claim 6, characterized in that 18-methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-one is administered by way of a daily dose of 1-100 µg.

8. Use according to Claim 7, characterized in that 18-methyl-15ß,16ß-methylene-

19-nor-20-spirox-4-en-3-one is administered by way of a daily dose of 2-50 µg.

9. Use of 18-methyl-6α,7α,15ß,16ß-dimethylene-19-nor-20-spirox-4-en-3-one according to Claim 3, characterized in that 18-methyl-6α,7α,15ß,16ß-dimethylene-19-nor-20-spirox-4-en-3-one is administered by the intrauterine route.

10. Use according to Claim 9, characterized in that 18-methyl-6α,7α,15ß,16ß-dimethylene-19-nor-20-spirox-4-en-3-one is administered using an intrauterine system.

11. Use according to Claim 10, characterized in that 18-methyl-6α,7α,15ß,16ß-dimethylene-19-nor-20-spirox-4-en-3-one is administered by way of a daily dose of 2-500 µg.


12. Use according to Claim 11, characterized in that 18-methyl-6α,7α,15ß,16ß-dimethylene-19-nor-20-spirox-4-en-3-one is administered by way of a daily dose of 2-200 µg.

13. Use according to Claim 12, characterized in that 18-methyl-6α,7α,15ß,16ß-dimethylene-19-nor-20-spirox-4-en-3-one is administered by way of a daily dose of 5-100 µg.

14. Intrauterine system comprising 18-methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-ones of formula 1 for use in the treatment of menorrhagia.

CLAIMS

1. 18-Methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-ones of the general formula I,



formula (1)

wherein R^6 and R^7 are a hydrogen atom or together are an α-methylene group, for use in the treatment of uterine bleeding disorders.

2. 18-Methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-one for use in the treatment of uterine bleeding disorders.

3. 18-Methyl-6α,7α,15ß,16ß-dimethylene-19-nor-20-spirox-4-en-3-one for use in the treatment of uterine bleeding disorders.

4. 18-methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-one for use in the treatment of menorrhagia, characterized in that 18-methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-one is administered by the intrauterine route.

5. 18-methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-one for use in the treatment of menorrhagia according to claim 4, wherein 18-methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-one is included in an intrauterine system.

6. 18-methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-one for use in the treatment of menorrhagia according to claim 4 or claim 5, wherein 18-methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-one is administered by way of a daily dose of 1-200 µg.

7. 18-methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-one for use in the treatment of menorrhagia according to claim 6, wherein 18-methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-one is administered by way of a daily dose of 1-100 µg.

8. 18-methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-one for use in the treatment of menorrhagia according to claim 7, wherein 18-methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-one is administered by way of a daily dose of 2-50 µg.

9. 18-methyl-6α,7α,15ß,16ß-dimethylene-19-nor-20-spirox-4-en-3-one for use in the treatment of menorrhagia, characterized in that 18-methyl-6α,7α,15ß,16ß-dimethylene-19-nor-20-spirox-4-en-3-one is administered by the intrauterine route.

10. 18-methyl-6α,7α,15ß,16ß-dimethylene-19-nor-20-spirox-4-en-3-one for use in the treatment of menorrhagia according to claim 9, wherein 18-methyl-6α,7α,15ß,16ß-dimethylene-19-nor-20-spirox-4-en-3-one is included in an intrauterine system.

11. 18-methyl-6α,7α,15ß,16ß-dimethylene-19-nor-20-spirox-4-en-3-one for use in the treatment of menorrhagia according to claim 9 or claim 10, wherein 18-methyl-6α,7α,15ß,16ß-dimethylene-19-nor-20-spirox-4-en-3-one is administered by way of a daily dose of 2-500 µg.

12. 18-methyl-6α,7α,15ß,16ß-dimethylene-19-nor-20-spirox-4-en-3-one for use in the treatment of menorrhagia according to claim 11, wherein 18-methyl-6α,7α,15ß,16ß-dimethylene-19-nor-20-spirox-4-en-3-one is administered by way of a daily dose of 2-200 µg.

13. 18-methyl-6α,7α,15ß,16ß-dimethylene-19-nor-20-spirox-4-en-3-one for use in the treatment of menorrhagia according to claim 12, wherein 18-methyl-6α,7α,15ß,16ß-dimethylene-19-nor-20-spirox-4-en-3-one is administered by way of a daily dose of 5-100 µg.